455 related articles for article (PubMed ID: 17401433)
1. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
Selivanova G; Wiman KG
Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
Bullock AN; Henckel J; Fersht AR
Oncogene; 2000 Mar; 19(10):1245-56. PubMed ID: 10713666
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
4. [Relevance of p53 protein and its mutations for novel strategies in cancer therapy].
Müller P; Nenutil R; Vojtĕsek B
Cas Lek Cesk; 2004; 143(5):313-7. PubMed ID: 15305766
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A; Rotter V
Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
[TBL] [Abstract][Full Text] [Related]
6. TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants.
Orgad S; Dimant H; Dor-On E; Azriel-Rosenfeld R; Benhar I; Solomon B
J Immunother; 2010; 33(2):146-54. PubMed ID: 20139776
[TBL] [Abstract][Full Text] [Related]
7. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
Wiman KG
Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
[TBL] [Abstract][Full Text] [Related]
8. Restoration of the transcription activation function to mutant p53 in human cancer cells.
Abarzúa P; LoSardo JE; Gubler ML; Spathis R; Lu YA; Felix A; Neri A
Oncogene; 1996 Dec; 13(11):2477-82. PubMed ID: 8957091
[TBL] [Abstract][Full Text] [Related]
9. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
10. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.
Kakudo Y; Shibata H; Otsuka K; Kato S; Ishioka C
Cancer Res; 2005 Mar; 65(6):2108-14. PubMed ID: 15781620
[TBL] [Abstract][Full Text] [Related]
11. [New transcription factor-based cancer therapy. Gene therapy, cell lysis, reactivation of p53 are the new approaches].
Wiman KG
Lakartidningen; 1997 Sep; 94(38):3268-72. PubMed ID: 9379794
[TBL] [Abstract][Full Text] [Related]
12. Specific binding of MAR/SAR DNA-elements by mutant p53.
Müller BF; Paulsen D; Deppert W
Oncogene; 1996 May; 12(9):1941-52. PubMed ID: 8649855
[TBL] [Abstract][Full Text] [Related]
13. [p53 as a molecular target for cancer therapy].
Ishioka C; Osada M; Gamo M; Kanamaru R
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2207-12. PubMed ID: 9422063
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53: the loaded gun.
Selivanova G
Curr Opin Investig Drugs; 2001 Aug; 2(8):1136-41. PubMed ID: 11892926
[TBL] [Abstract][Full Text] [Related]
15. Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast.
Grochova D; Vankova J; Damborsky J; Ravcukova B; Smarda J; Vojtesek B; Smardova J
Oncogene; 2008 Feb; 27(9):1243-52. PubMed ID: 17724467
[TBL] [Abstract][Full Text] [Related]
16. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein.
Sugikawa E; Tsunoda S; Nakanishi N; Ohashi M
Anticancer Res; 2001; 21(4A):2671-5. PubMed ID: 11724337
[TBL] [Abstract][Full Text] [Related]
17. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein.
Vojtesek B; Dolezalova H; Lauerova L; Svitakova M; Havlis P; Kovarik J; Midgley CA; Lane DP
Oncogene; 1995 Jan; 10(2):389-93. PubMed ID: 7530828
[TBL] [Abstract][Full Text] [Related]
18. Extract from Asteraceae Brachylaena ramiflora induces apoptosis preferentially in mutant p53-expressing human tumor cells.
Karimi M; Conserva F; Mahmoudi S; Bergman J; Wiman KG; Bykov VJ
Carcinogenesis; 2010 Jun; 31(6):1045-53. PubMed ID: 20427345
[TBL] [Abstract][Full Text] [Related]
19. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
[TBL] [Abstract][Full Text] [Related]
20. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features.
Walker DR; Bond JP; Tarone RE; Harris CC; Makalowski W; Boguski MS; Greenblatt MS
Oncogene; 1999 Jan; 18(1):211-8. PubMed ID: 9926936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
